Novavax Inc. (NASDAQ: NVAX)’s stock price has increased by 1.19 compared to its previous closing price of 5.90. but the company has seen a -9.13% decline in its stock price over the last five trading sessions. Barron’s reported on 02/28/23 that Novavax: ‘Substantial Doubt’ Around Ability to Continue
Is It Worth Investing in Novavax Inc. (NASDAQ: NVAX) Right Now?
Moreover, the 36-month beta value for NVAX is 1.81. Analysts have varying opinions on the stock, with 3 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 1 as “sell.”
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
The average price recommended by analysts for Novavax Inc. (NVAX) is $50.80, which is $44.83 above the current market price. The public float for NVAX is 78.14M and currently, short sellers hold a 43.65% of that float. On March 17, 2023, NVAX’s average trading volume was 7.29M shares.
NVAX’s Market Performance
NVAX stock saw a decrease of -9.13% in the past week, with a monthly decline of -39.88% and a quarterly a decrease of -65.31%. The volatility ratio for the week is 9.90%, and the volatility levels for the last 30 days are 7.39% for Novavax Inc. (NVAX). The simple moving average for the last 20 days is -25.02% for NVAX stock, with a simple moving average of -78.16% for the last 200 days.
Analysts’ Opinion of NVAX
Many brokerage firms have already submitted their reports for NVAX stocks, with B. Riley Securities repeating the rating for NVAX by listing it as a “Neutral.” The predicted price for NVAX in the upcoming period, according to B. Riley Securities is $10 based on the research report published on March 01st of the current year 2023.
B. Riley Securities, on the other hand, stated in their research note that they expect to see NVAX reach a price target of $37, previously predicting the price at $74. The rating they have provided for NVAX stocks is “Buy” according to the report published on January 09th, 2023.
H.C. Wainwright gave a rating of “Buy” to NVAX, setting the target price at $110 in the report published on December 30th of the previous year.
NVAX Trading at -39.88% from the 50-Day Moving Average
After a stumble in the market that brought NVAX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.03% of loss for the given period.
Volatility was left at 7.39%, however, over the last 30 days, the volatility rate increased by 9.90%, as shares sank -41.41% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -39.02% lower at present.
During the last 5 trading sessions, NVAX fell by -9.13%, which changed the moving average for the period of 200-days by -87.32% in comparison to the 20-day moving average, which settled at $7.75. In addition, Novavax Inc. saw -41.93% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at NVAX starting from Glenn Gregory M, who purchase 1,000 shares at the price of $6.50 back on Mar 10. After this action, Glenn Gregory M now owns 14,473 shares of Novavax Inc., valued at $6,500 using the latest closing price.
Glenn Gregory M, the President, R&D of Novavax Inc., purchase 2,000 shares at $7.04 during a trade that took place back on Mar 07, which means that Glenn Gregory M is holding 13,473 shares at $14,088 based on the most recent closing price.
Stock Fundamentals for NVAX
Current profitability levels for the company are sitting at:
- -64.27 for the present operating margin
- +43.55 for the gross margin
The net margin for Novavax Inc. stands at -41.15. Equity return is now at value 169.60, with -26.40 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 0.69.
To wrap up, the performance of Novavax Inc. (NVAX) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.